Global menu

Our global pages


We acted as advisor to Revenio Group Plc in a corporate acquisition

  • Finland


    We acted as advisor to Revenio Group Plc, which is listed on the Nasdaq Helsinki, when it signed an agreement to purchase 100 per cent of the share of the Australian CERA Technologies Pty Ltd (Oculo).

    Oculo specializes in the development of software for the secure and real-time sharing of clinical imaging, referrals, and other clinical communications among healthcare professionals. Revenio Group Oyj is a Finnish health technology group whose core business consists of intraocular pressure measurement devices.

    The acquisition is expected to close in the beginning of the second quarter of 2021, provided that certain customary conditions are met. In addition to this, we assisted in LTI and AML matters. The value of the acquisition is AUD 18.5 million, or approximately MEUR 12.0.

    Harri Tolppanen and Juha Kujala were responsible for the project, and our team also included Jarkko Hankaa, Merja Blankenstein, Torsti Lakari and Linda Miettinen as well as Eugene Fung, Melanie Mitchell and Sarah Beattie from our Australian partner office Thompson Geer.

    Read more about Revenio Group Plc's release here.

    This information is for guidance purposes only and should not be regarded as a substitute for taking legal advice. Please refer to the full terms and conditions on our website.

    < Go back